[PDF][PDF] HIV antiretroviral drug resistance in Africa
JN Nkengasong, C Adje-Toure, PJ Weidle - Aids Rev, 2004 - researchgate.net
Highly active antiretroviral therapy (HAART) has dramatically reduced mortality and
morbidity in HIV-infected persons in developed countries. Although the use of HAART …
morbidity in HIV-infected persons in developed countries. Although the use of HAART …
The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa
RL Hamers, I Derdelinckx, M van Vugt… - Antiviral …, 2008 - journals.sagepub.com
Access to highly active antiretroviral therapy (HAART) for persons infected with HIV in sub-
Saharan Africa has greatly improved over the past few years. However, data on long-term …
Saharan Africa has greatly improved over the past few years. However, data on long-term …
Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa
C Seyler, C Adjé-Touré, E Messou, N Dakoury-Dogbo… - Aids, 2007 - journals.lww.com
Objectives: To analyse the association between the presence of resistance mutations and
treatment outcomes. The impact of HIV-1 drug resistance mutations in African adults on …
treatment outcomes. The impact of HIV-1 drug resistance mutations in African adults on …
Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south
JP Moatti, B Spire, M Kazatchkine - Aids, 2004 - journals.lww.com
Here we review the available evidence on adherence to highly active antiretroviral therapy
(HAART) and its relationship with the risk of the dissemination of HIV-resistant viral strains in …
(HAART) and its relationship with the risk of the dissemination of HIV-resistant viral strains in …
Surprisingly high prevalence of subtype C and specific HIV-1 subtype/CRF distribution in men having sex with men in Senegal
HD Ndiaye, C Toure-Kane, N Vidal… - JAIDS Journal of …, 2009 - journals.lww.com
Background: Recent reports showed the high vulnerability for HIV infection of men who have
sex with men (MSM) in Africa. Here, we report the HIV-1 variants that circulate among MSM …
sex with men (MSM) in Africa. Here, we report the HIV-1 variants that circulate among MSM …
The origin and evolutionary history of HIV-1 subtype C in Senegal
M Jung, N Leye, N Vidal, D Fargette, H Diop… - PloS one, 2012 - journals.plos.org
Background The classification of HIV-1 strains in subtypes and Circulating Recombinant
Forms (CRFs) has helped in tracking the course of the HIV pandemic. In Senegal, which is …
Forms (CRFs) has helped in tracking the course of the HIV pandemic. In Senegal, which is …
Estimating the rate of accumulating drug resistance mutations in the HIV genome
RS Braithwaite, S Shechter, CCH Chang… - Value in …, 2007 - Wiley Online Library
Objective: HIV mutation accumulation has great implications for pharmacoeconomics and
clinical care, yet scarcity of data has hindered its representation in decision analytic models …
clinical care, yet scarcity of data has hindered its representation in decision analytic models …
Characterization of drug‐resistance mutations in HIV‐1 isolates from non‐HAART and HAART treated patients in Burkina Faso
WM Nadembega, S Giannella, J Simporé… - Journal of medical …, 2006 - Wiley Online Library
Non‐B HIV subtypes have been estimated to account for 88% of HIV infections in the world.
These subtypes are particularly relevant in view of the availability of antiretroviral (ARV) …
These subtypes are particularly relevant in view of the availability of antiretroviral (ARV) …
Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?
J Martinez, P Coplan, MA Wainberg - Antiviral research, 2006 - Elsevier
Antiviral drugs that act at specific sites within the HIV life cycle have important rationale for
development as anti-HIV microbicides. However, to be effective, such drugs must act by …
development as anti-HIV microbicides. However, to be effective, such drugs must act by …
HIV-1 subtype C drug-resistance background among ARV-naive adults in Botswana
H Bussmann, V Novitsky, W Wester… - Antiviral Chemistry …, 2005 - journals.sagepub.com
Current HIV-1 antiretroviral (ARV) drug resistance knowledge is limited to HIV-1 subtype B
(HIV-1B). We addressed whether unique genetic and phenotypic properties of HIV-1 …
(HIV-1B). We addressed whether unique genetic and phenotypic properties of HIV-1 …